Crestor and Diphenhydramine Interaction: What the Evidence Actually Shows

Rosuvastatin (brand name Crestor, an HMG-CoA reductase inhibitor, "statin") and diphenhydramine (brand name Benadryl, a first-generation H1 antihistamine) are metabolized and transported through different pathways in the liver. Rosuvastatin's disposition depends mainly on hepatic uptake transporters, not on the CYP2D6 enzyme that diphenhydramine primarily uses. No pharmacokinetic interaction between the two drugs has been established, and neither the FDA label for Crestor nor the major clinical drug-interaction databases (Lexicomp, Micromedex) list diphenhydramine as an interacting agent. That does not mean the pairing is risk-free for every patient; it means the risk, where it exists, comes from diphenhydramine's own sedative and anticholinergic effects, not from a drug-drug interaction with the statin.

The direct answer

Rosuvastatin clears the body largely unchanged, with only a minor contribution from CYP-mediated metabolism, and it relies on hepatic uptake transporters (OATP1B1, OATP1B3) and an efflux transporter (BCRP) rather than CYP2D6 or CYP3A4 [FDA label]. Diphenhydramine is metabolized primarily through CYP2D6 and does not appear on the FDA label's list of drugs that raise rosuvastatin exposure through transporter inhibition. Because the two drugs do not share the pathway that matters most for rosuvastatin levels, no dose adjustment is described in FDA labeling or major interaction references for this combination. This is a statement about pharmacokinetics, not a guarantee against side effects; diphenhydramine can still cause sedation and anticholinergic effects on its own, particularly in older adults.

Why people ask this question

Rosuvastatin has a genuine and well-documented interaction profile with drugs that block the transporters it depends on for hepatic uptake. Cyclosporine, gemfibrozil, and certain HIV protease inhibitors are named on the FDA label with corresponding dose limits because they meaningfully raise rosuvastatin blood levels (per current FDA prescribing information for Crestor). Patients who know statins carry interaction risk reasonably wonder whether an over-the-counter antihistamine taken for allergies, insomnia, or cold symptoms belongs on that same watch list.

It does not, based on the mechanism. Diphenhydramine is not reported as a significant inhibitor of OATP1B1, OATP1B3, or BCRP, which are the transporters that drive the clinically important rosuvastatin interactions. It is a CYP2D6 substrate and inhibitor, and rosuvastatin does not depend on CYP2D6 for clearance. The enzyme system that diphenhydramine affects and the transport system that governs rosuvastatin exposure are largely non-overlapping.

What CYP and transporter data actually show

Rosuvastatin undergoes minimal phase I hepatic metabolism. The FDA label describes the drug as eliminated mostly unchanged, with a small contribution from CYP2C9 and an even smaller one from CYP2C19; CYP2D6 is not identified as a meaningful metabolic route for rosuvastatin. Diphenhydramine's own metabolism runs primarily through CYP2D6, with lesser contributions from other CYP enzymes, followed by renal excretion of its metabolites. Because CYP2D6 is not a rosuvastatin pathway, diphenhydramine's CYP2D6 inhibition has no direct bearing on rosuvastatin levels.

There is a narrow theoretical overlap at CYP2C9, where rosuvastatin has a minor metabolic role and diphenhydramine has been described as a weak inhibitor in some pharmacology references. Because CYP2C9 accounts for only a small fraction of rosuvastatin clearance, even a real CYP2C9 effect from diphenhydramine would be expected to produce a small change in rosuvastatin exposure at most. This is a plausible, low-magnitude effect rather than an established clinical concern, and it has not been directly studied in a published pharmacokinetic trial of the two drugs together, at least none identified in this review. That absence of a dedicated interaction study is itself part of the evidence picture: the combination has not been formally tested, but the mechanistic case for a meaningful interaction is weak.

By contrast, the interactions that do require dose adjustment on the Crestor label (cyclosporine, gemfibrozil, certain protease inhibitors) work through transporter inhibition at OATP1B1/1B3 and, in some cases, BCRP. That is a different and more consequential mechanism than anything diphenhydramine is known to do.

Where the pharmacodynamic caution actually lives

Rosuvastatin itself has no sedative or anticholinergic activity. Diphenhydramine does: it causes dose-dependent drowsiness, cognitive slowing, dry mouth, urinary retention, and constipation through histamine H1 blockade and muscarinic antagonism. These effects are a property of diphenhydramine alone and are not amplified by rosuvastatin.

The American Geriatrics Society's Beers Criteria for potentially inappropriate medication use in older adults recommend avoiding diphenhydramine in adults 65 and older because of its strong anticholinergic burden and association with confusion and falls. That recommendation applies regardless of what statin, if any, the patient is taking. A patient on rosuvastatin who is also 65 or older should be cautious about diphenhydramine for the same reason any older adult should be cautious about it, not because of a drug interaction with the statin.

Statin-associated muscle symptoms are the most clinically relevant adverse effect associated with rosuvastatin. Antihistamines are not established as a risk factor for statin muscle symptoms in the risk-factor lists published by lipid specialty groups; the recognized risk factors relate more to age, thyroid status, kidney function, statin dose, and interacting CYP3A4 inhibitors for statins that use that pathway (rosuvastatin is not one of them).

Evidence-status assessment for this pairing

Practical guidance

No dose adjustment for rosuvastatin or diphenhydramine is described in FDA labeling for this combination, and major interaction databases do not flag it. That said, the following points are worth discussing with a pharmacist or prescriber rather than assuming:

• If diphenhydramine is being used for routine allergy symptoms, a second-generation antihistamine (cetirizine, loratadine, fexofenadine) is often preferred for its lower sedation and anticholinergic burden, independent of any statin interaction concern.
• Adults 65 and older, or anyone already taking other anticholinergic medications (certain antidepressants, bladder antispasmodics, some antipsychotics), should discuss whether diphenhydramine is appropriate at all, since the concern there is cumulative anticholinergic load, not an interaction with rosuvastatin.
• Diphenhydramine's CYP2D6 inhibition is more relevant to other CYP2D6-dependent drugs a patient may be taking (for example, codeine or certain beta-blockers) than to rosuvastatin. A full medication list review is the way to catch that, not a rosuvastatin-specific check.
• Anyone with new or unusual muscle pain, weakness, or dark urine while on rosuvastatin should contact their prescriber regardless of antihistamine use, since these can be signs of statin-associated muscle injury that need prompt evaluation.
• People with kidney or liver impairment may clear either drug more slowly. This is a property of each drug's own handling in that condition, not evidence that the two drugs interact with each other.

What is established, what is not, and where the boundary sits

It is established that rosuvastatin and diphenhydramine use largely separate elimination pathways, and that the drugs the FDA label identifies as raising rosuvastatin exposure work by inhibiting hepatic transporters that diphenhydramine does not meaningfully affect. It is not established, in the sense of a dedicated clinical trial, that co-administration produces zero pharmacokinetic effect at every dose in every patient; the honest position is that no meaningful interaction has been identified and none is mechanistically expected. Anyone with a known SLCO1B1 or ABCG2 genetic variant affecting statin transport, or anyone on multiple interacting medications, should have their full regimen reviewed by a pharmacist rather than relying on a single-pair check like this one.

This information does not replace a conversation with a pharmacist or prescriber, particularly for patients with kidney or liver disease, multiple medications, or a history of statin-related muscle symptoms.

This article is a draft prepared for pharmacist and physician review. It has not yet received qualified medical review. Specific numeric claims about fold-changes in drug exposure should be checked against the current FDA label before publication.